IMMUNIC, INC. Files 8-K Report
Ticker: IMUX · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1280776
| Field | Detail |
|---|---|
| Company | Immunic, INC. (IMUX) |
| Form Type | 8-K |
| Filed Date | Oct 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, financials
TL;DR
IMMUNIC, INC. filed an 8-K, mostly financial docs. No major news.
AI Summary
On October 22, 2024, IMMUNIC, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.
Why It Matters
This filing indicates IMMUNIC, INC. is fulfilling its reporting obligations with the SEC, providing necessary financial and exhibit information to the public.
Risk Assessment
Risk Level: low — The filing is a routine SEC disclosure and does not contain information that suggests an immediate change in risk for the company.
Key Players & Entities
- IMMUNIC, INC. (company) — Registrant
- October 22, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1200 Avenue of the Americas, Suite 200 New York, NY 10036 (address) — Principal executive offices
- (332) 255-9818 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for IMMUNIC, INC.?
The filing is primarily for 'Other Events' and 'Financial Statements and Exhibits', indicating routine SEC reporting.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is October 22, 2024.
In which U.S. state is IMMUNIC, INC. incorporated?
IMMUNIC, INC. is incorporated in Delaware.
What is the principal executive office address for IMMUNIC, INC.?
The principal executive office is located at 1200 Avenue of the Americas, Suite 200, New York, NY 10036.
Does this 8-K filing announce any new products or significant business developments?
Based on the provided text, this filing is focused on financial statements and exhibits, and does not explicitly announce new products or significant business developments.
Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-10-22 06:45:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC In
Filing Documents
- e663960_8k-immunic.htm (8-K) — 21KB
- e663960_ex99-1.htm (EX-99.1) — 19KB
- e663960_ex99-2.htm (EX-99.2) — 12KB
- image1.jpg (GRAPHIC) — 5KB
- slide1.jpg (GRAPHIC) — 170KB
- slide2.jpg (GRAPHIC) — 344KB
- slide3.jpg (GRAPHIC) — 112KB
- slide4.jpg (GRAPHIC) — 182KB
- slide5.jpg (GRAPHIC) — 59KB
- slide6.jpg (GRAPHIC) — 194KB
- slide7.jpg (GRAPHIC) — 140KB
- slide8.jpg (GRAPHIC) — 198KB
- slide9.jpg (GRAPHIC) — 163KB
- slide10.jpg (GRAPHIC) — 142KB
- slide11.jpg (GRAPHIC) — 43KB
- slide12.jpg (GRAPHIC) — 42KB
- slide13.jpg (GRAPHIC) — 149KB
- slide14.jpg (GRAPHIC) — 158KB
- slide15.jpg (GRAPHIC) — 165KB
- slide16.jpg (GRAPHIC) — 120KB
- 0001193805-24-001257.txt ( ) — 3520KB
- imux-20241022.xsd (EX-101.SCH) — 3KB
- imux-20241022_lab.xml (EX-101.LAB) — 33KB
- imux-20241022_pre.xml (EX-101.PRE) — 22KB
- e663960_8k-immunic_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events On October 22, 2024, Immunic, Inc. (the "Company") issued a press release and presentation reporting on the positive outcome of the non-binding, interim futility analysis of its phase 3 ENSURE program, which studies the Company's lead asset, nuclear receptor related 1 activator, vidofludimus calcium (IMU-838), in respect of the treatment of relapsing multiple sclerosis. The press release and presentation are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits Exhibit Description 99.1 Press Release, dated October 22, 2024. 99.2 Presentation, dated October 22, 2024. 104 Cover Page to this Current Report on Form 8-K in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: October 22, 2024 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer